^
    7d
    Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jul 2025
    Enrollment open • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yidafan (ivonescimab)
    7d
    A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects (clinicaltrials.gov)
    P1, N=108, Recruiting, Akeso
    New P1 trial
    |
    Yidafan (ivonescimab)
    7d
    Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Airuikai (glecirasib) • Yidafan (ivonescimab)
    8d
    ASCEND: CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=290, Not yet recruiting, Crescent Biopharma, Inc.
    New P1/2 trial
    9d
    BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=177, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2028 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Lucentis (ranibizumab)
    9d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=800, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab)
    10d
    Pregonda: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P1, N=151, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    10d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=550, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tecentriq (atezolizumab)
    12d
    A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, Axion Bio, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    12d
    PRIDE: Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma (clinicaltrials.gov)
    P2, N=146, Recruiting, University Hospital Tuebingen | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Apr 2027 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    Avastin (bevacizumab)
    13d
    An Assistant Model for Anti-VEGF Therapy Decision (clinicaltrials.gov)
    P=N/A, N=160, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    13d
    Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization. (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1/2 trial